Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy

Soo Ryang Kim; Jun Saito; Susumu Imoto; Takamitsu Komaki; Yoshiaki Nagata; Ke Ih Kim; Noriko Sasase; Noriyo Kimura; Kanako Sasatani; Erika Konishi; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Ahmed El-Shamy; Yasuhito Tanaka; Masahiko Sugano; Masanori Sakashita; Akira Nakamura; Shinobu Tsuchida; Tetsuya Makino; Tetsumi Kawada; Takatoshi Nakajima; Teruhisa Morikawa; Akira Muramatsu; Hiroshi Kasugai; Hak Hotta; Masatoshi Kudo

doi:10.1159/000333209

Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy

Soo Ryang Kim, Jun Saito, Susumu Imoto, Takamitsu Komaki, Yoshiaki Nagata, Ke Ih Kim, Noriko Sasase, Noriyo Kimura, Kanako Sasatani, Erika Konishi, Yutaka Hasegawa, Aya Fujinami, Mitsuhiro Ohta, Ahmed El-Shamy, Yasuhito Tanaka, Masahiko Sugano, Masanori Sakashita, Akira Nakamura, Shinobu Tsuchida, Tetsuya MakinoTetsumi Kawada, Takatoshi Nakajima, Teruhisa Morikawa, Akira Muramatsu, Hiroshi Kasugai, Hak Hotta, Masatoshi Kudo

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background and Aims: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. Methods: Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) and relapse (n = 8) groups. DFPP was used in combination with IFN-β/RBV with subsequent administration of PEG-IFN-α2a/RBV therapy (DFPP + IFN-β/RBV then PEG-IFN/RBV). Early viral dynamics was assessed, focusing especially on complete early virological response (cEVR) associated with sustained virological response. Additionally, the interleukin 28B gene, the IFN/RBV resistance-determining region, the IFN sensitivity-determining region and the core regions were analyzed. Results: Rapid virological response was achieved in 0% (0/12) of NVR and in 75% (6/8) of relapse patients, with a significant difference between the two groups (p = 0.001). Similarly, cEVR was achieved in 8% (1/12) of NVR and in 88% (7/8) of relapse patients, with a significant difference between the two groups (p = 0.037). By multivariate logistic regression analysis, interleukin-28B major was a significant determiner of cEVR (odds ratio = 24.19, p = 0.037). Conclusion: DFPP + IFN-β/RBV then PEG-IFN/RBV therapy is indicated more for relapse than for NVR patients.

Original language	English
Pages (from-to)	10-16
Number of pages	7
Journal	Digestion
Volume	84
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000333209
State	Published - Dec 2011
Externally published	Yes

Keywords

Complete early virological response
Double-filtration plasmapheresis
Interferon-β
Null virological response
Rapid virological response
Relapse
Ribavirin
Viral dynamics

Access to Document

10.1159/000333209

Cite this

Kim, S. R., Saito, J., Imoto, S., Komaki, T., Nagata, Y., Kim, K. I., Sasase, N., Kimura, N., Sasatani, K., Konishi, E., Hasegawa, Y., Fujinami, A., Ohta, M., El-Shamy, A., Tanaka, Y., Sugano, M., Sakashita, M., Nakamura, A., Tsuchida, S., ... Kudo, M. (2011). Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy. Digestion, 84(SUPPL. 1), 10-16. https://doi.org/10.1159/000333209

@article{3491f90746064ad384e1fb01d9b8e124,

title = "Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy",

abstract = "Background and Aims: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. Methods: Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) and relapse (n = 8) groups. DFPP was used in combination with IFN-β/RBV with subsequent administration of PEG-IFN-α2a/RBV therapy (DFPP + IFN-β/RBV then PEG-IFN/RBV). Early viral dynamics was assessed, focusing especially on complete early virological response (cEVR) associated with sustained virological response. Additionally, the interleukin 28B gene, the IFN/RBV resistance-determining region, the IFN sensitivity-determining region and the core regions were analyzed. Results: Rapid virological response was achieved in 0% (0/12) of NVR and in 75% (6/8) of relapse patients, with a significant difference between the two groups (p = 0.001). Similarly, cEVR was achieved in 8% (1/12) of NVR and in 88% (7/8) of relapse patients, with a significant difference between the two groups (p = 0.037). By multivariate logistic regression analysis, interleukin-28B major was a significant determiner of cEVR (odds ratio = 24.19, p = 0.037). Conclusion: DFPP + IFN-β/RBV then PEG-IFN/RBV therapy is indicated more for relapse than for NVR patients.",

keywords = "Complete early virological response, Double-filtration plasmapheresis, Interferon-β, Null virological response, Rapid virological response, Relapse, Ribavirin, Viral dynamics",

author = "Kim, {Soo Ryang} and Jun Saito and Susumu Imoto and Takamitsu Komaki and Yoshiaki Nagata and Kim, {Ke Ih} and Noriko Sasase and Noriyo Kimura and Kanako Sasatani and Erika Konishi and Yutaka Hasegawa and Aya Fujinami and Mitsuhiro Ohta and Ahmed El-Shamy and Yasuhito Tanaka and Masahiko Sugano and Masanori Sakashita and Akira Nakamura and Shinobu Tsuchida and Tetsuya Makino and Tetsumi Kawada and Takatoshi Nakajima and Teruhisa Morikawa and Akira Muramatsu and Hiroshi Kasugai and Hak Hotta and Masatoshi Kudo",

year = "2011",

month = dec,

doi = "10.1159/000333209",

language = "English",

volume = "84",

pages = "10--16",

journal = "Digestion",

issn = "0012-2823",

publisher = "S. Karger AG",

number = "SUPPL. 1",

}

Kim, SR, Saito, J, Imoto, S, Komaki, T, Nagata, Y, Kim, KI, Sasase, N, Kimura, N, Sasatani, K, Konishi, E, Hasegawa, Y, Fujinami, A, Ohta, M, El-Shamy, A, Tanaka, Y, Sugano, M, Sakashita, M, Nakamura, A, Tsuchida, S, Makino, T, Kawada, T, Nakajima, T, Morikawa, T, Muramatsu, A, Kasugai, H, Hotta, H & Kudo, M 2011, 'Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy', Digestion, vol. 84, no. SUPPL. 1, pp. 10-16. https://doi.org/10.1159/000333209

TY - JOUR

T1 - Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy

AU - Kim, Soo Ryang

AU - Saito, Jun

AU - Imoto, Susumu

AU - Komaki, Takamitsu

AU - Nagata, Yoshiaki

AU - Kim, Ke Ih

AU - Sasase, Noriko

AU - Kimura, Noriyo

AU - Sasatani, Kanako

AU - Konishi, Erika

AU - Hasegawa, Yutaka

AU - Fujinami, Aya

AU - Ohta, Mitsuhiro

AU - El-Shamy, Ahmed

AU - Tanaka, Yasuhito

AU - Sugano, Masahiko

AU - Sakashita, Masanori

AU - Nakamura, Akira

AU - Tsuchida, Shinobu

AU - Makino, Tetsuya

AU - Kawada, Tetsumi

AU - Nakajima, Takatoshi

AU - Morikawa, Teruhisa

AU - Muramatsu, Akira

AU - Kasugai, Hiroshi

AU - Hotta, Hak

AU - Kudo, Masatoshi

PY - 2011/12

Y1 - 2011/12

N2 - Background and Aims: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. Methods: Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) and relapse (n = 8) groups. DFPP was used in combination with IFN-β/RBV with subsequent administration of PEG-IFN-α2a/RBV therapy (DFPP + IFN-β/RBV then PEG-IFN/RBV). Early viral dynamics was assessed, focusing especially on complete early virological response (cEVR) associated with sustained virological response. Additionally, the interleukin 28B gene, the IFN/RBV resistance-determining region, the IFN sensitivity-determining region and the core regions were analyzed. Results: Rapid virological response was achieved in 0% (0/12) of NVR and in 75% (6/8) of relapse patients, with a significant difference between the two groups (p = 0.001). Similarly, cEVR was achieved in 8% (1/12) of NVR and in 88% (7/8) of relapse patients, with a significant difference between the two groups (p = 0.037). By multivariate logistic regression analysis, interleukin-28B major was a significant determiner of cEVR (odds ratio = 24.19, p = 0.037). Conclusion: DFPP + IFN-β/RBV then PEG-IFN/RBV therapy is indicated more for relapse than for NVR patients.

AB - Background and Aims: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. Methods: Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) and relapse (n = 8) groups. DFPP was used in combination with IFN-β/RBV with subsequent administration of PEG-IFN-α2a/RBV therapy (DFPP + IFN-β/RBV then PEG-IFN/RBV). Early viral dynamics was assessed, focusing especially on complete early virological response (cEVR) associated with sustained virological response. Additionally, the interleukin 28B gene, the IFN/RBV resistance-determining region, the IFN sensitivity-determining region and the core regions were analyzed. Results: Rapid virological response was achieved in 0% (0/12) of NVR and in 75% (6/8) of relapse patients, with a significant difference between the two groups (p = 0.001). Similarly, cEVR was achieved in 8% (1/12) of NVR and in 88% (7/8) of relapse patients, with a significant difference between the two groups (p = 0.037). By multivariate logistic regression analysis, interleukin-28B major was a significant determiner of cEVR (odds ratio = 24.19, p = 0.037). Conclusion: DFPP + IFN-β/RBV then PEG-IFN/RBV therapy is indicated more for relapse than for NVR patients.

KW - Complete early virological response

KW - Double-filtration plasmapheresis

KW - Interferon-β

KW - Null virological response

KW - Rapid virological response

KW - Relapse

KW - Ribavirin

KW - Viral dynamics

UR - http://www.scopus.com/inward/record.url?scp=83755172696&partnerID=8YFLogxK

U2 - 10.1159/000333209

DO - 10.1159/000333209

M3 - Article

C2 - 22156480

AN - SCOPUS:83755172696

SN - 0012-2823

VL - 84

SP - 10

EP - 16

JO - Digestion

JF - Digestion

IS - SUPPL. 1

ER -

Double-filtration plasmapheresis plus interferon-β for HCV-1b patients with non-sustained virological response to previous combination therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this